106 related articles for article (PubMed ID: 11311231)
1. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor.
Tan DC; Kini RM; Jois SD; Lim DK; Xin L; Ge R
FEBS Lett; 2001 Apr; 494(3):150-6. PubMed ID: 11311231
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor fails to acutely modulate endothelial permeability during early angiogenesis in the chick chorioallantoic membrane.
DeFouw LM; DeFouw DO
Microvasc Res; 2000 Nov; 60(3):212-21. PubMed ID: 11078637
[TBL] [Abstract][Full Text] [Related]
3. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
[TBL] [Abstract][Full Text] [Related]
4. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
Hetian L; Ping A; Shumei S; Xiaoying L; Luowen H; Jian W; Lin M; Meisheng L; Junshan Y; Chengchao S
J Biol Chem; 2002 Nov; 277(45):43137-42. PubMed ID: 12183450
[TBL] [Abstract][Full Text] [Related]
5. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
6. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor.
Zilberberg L; Shinkaruk S; Lequin O; Rousseau B; Hagedorn M; Costa F; Caronzolo D; Balke M; Canron X; Convert O; Laïn G; Gionnet K; Goncalvès M; Bayle M; Bello L; Chassaing G; Deleris G; Bikfalvi A
J Biol Chem; 2003 Sep; 278(37):35564-73. PubMed ID: 12837752
[TBL] [Abstract][Full Text] [Related]
7. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
8. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity.
Sasaki T; Larsson H; Tisi D; Claesson-Welsh L; Hohenester E; Timpl R
J Mol Biol; 2000 Sep; 301(5):1179-90. PubMed ID: 10966814
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.
Piossek C; Schneider-Mergener J; Schirner M; Vakalopoulou E; Germeroth L; Thierauch KH
J Biol Chem; 1999 Feb; 274(9):5612-9. PubMed ID: 10026178
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
12. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
14. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
15. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli.
Siemeister G; Schnurr B; Mohrs K; Schächtele C; Marmé D; Martiny-Baron G
Biochem Biophys Res Commun; 1996 May; 222(2):249-55. PubMed ID: 8670191
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
Deroanne CF; Bonjean K; Servotte S; Devy L; Colige A; Clausse N; Blacher S; Verdin E; Foidart JM; Nusgens BV; Castronovo V
Oncogene; 2002 Jan; 21(3):427-36. PubMed ID: 11821955
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
Hernández GL; Volpert OV; Iñiguez MA; Lorenzo E; Martínez-Martínez S; Grau R; Fresno M; Redondo JM
J Exp Med; 2001 Mar; 193(5):607-20. PubMed ID: 11238591
[TBL] [Abstract][Full Text] [Related]
18. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
20. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.
Starovasnik MA; Christinger HW; Wiesmann C; Champe MA; de Vos AM; Skelton NJ
J Mol Biol; 1999 Oct; 293(3):531-44. PubMed ID: 10543948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
